Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure ...(ime or that express beliefs expectations...),Health

Date:8/26/2009

ime or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company's products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.

CardioMEMS is a registered trademark of CardioMEMS, Inc.

'/>"/>

SOURCE CardioMEMS, Inc. Copyright©2009 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3
Related medicine technology :

1. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
2. Karolinska Development Portfolio Company Launches GMP Facility for Particulate Manufacturing
3. European Division of Global Top 20 Pharmaceutical Company Awards Phase III Trial to DATATRAK
4. Infant Formula Company Teams With the University of Virginia Pediatrics Department to Conduct Clinical Studies
5. Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Companys Toolbox
6. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
7. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
8. Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments
9. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
10. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
11. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives